MARUHO CO., LTD.

Nielsen BioSciences Completes Phase 3 Enrollment for Novel Wart Treatment CANDIN

3 months ago

• Nielsen BioSciences has completed enrollment of 325 subjects across the US and Japan in a Phase 3 trial evaluating CANDIN for common wart treatment, with results expected by end of 2025. • The trial investigates CANDIN, a Candida albicans-based immunological therapy, as a potential alternative to traditional wart removal methods that can damage skin. • The study aims to assess complete wart resolution in patients aged 12 and older through bi-weekly injections, with Nielsen planning US regulatory submissions and partnership with Maruho for Japanese commercialization.

Rosacea Therapeutics Pipeline Shows Promise with Emerging Therapies

4 months ago

• Over 25 companies are developing novel rosacea treatments, indicating a robust pipeline. • Key emerging therapies like Epsolay, M 1220, and BMX-010 are expected to significantly impact the rosacea market. • Sol-Gel Technologies and Maruho Co., Ltd. are among the leading companies in developing advanced-stage rosacea drugs. • Recent regulatory approvals, such as Zydus Lifesciences' metronidazole topical cream, offer new treatment options.

Journey Medical's Emrosi Receives FDA Approval for Rosacea Treatment

6 months ago

• Journey Medical's Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) has been approved by the FDA for treating inflammatory lesions of rosacea in adults. • The launch of Emrosi is anticipated in late Q1 or early Q2 of 2025, following the completion of manufacturing activities and deployment of the dermatology sales force. • Clinical data presented at a recent conference highlighted Emrosi's higher dermal concentration compared to oral Doxycycline, potentially leading to clinically meaningful impact. • Journey Medical reported $14.6 million in total revenues for Q3 2024, with a focus on commercializing core dermatology products and preparing for the launch of Emrosi.

Rosacea Therapeutics: Emerging Therapies and Market Outlook

7 months ago

• Over 25 companies are actively involved in developing novel rosacea treatments, indicating a robust pipeline. • Key emerging therapies like Epsolay, M 1220, and BMX-010 are expected to significantly impact the rosacea market in the coming years. • Sol-Gel Technologies and Maruho Co., Ltd. are among the leading companies in advancing rosacea drug candidates through clinical development. • Recent regulatory approvals, such as Zydus Lifesciences' metronidazole topical cream, provide additional treatment options for rosacea patients.

Rosacea Pipeline Analysis 2024: Insights into Therapeutics Development

a year ago

The 2024 Rosacea Pipeline Analysis report by DelveInsight highlights the ongoing clinical development activities and growth prospects in the Rosacea Therapeutics Market. It details the involvement of over 25 key pharma and biotech companies, including Sol-Gel Technologies, in developing more than 25 pipeline drugs. The report covers various stages of clinical development, mechanisms of action, and molecule types, offering a comprehensive overview of the current and future landscape of Rosacea treatment.